Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)
D. Spigel, K. Goto, D. Camidge, Y. Elamin, A. D. de Langen, N. Leighl, A. Minchom, Z. Piotrowska, D. Planchard, K. Reckamp, F. Albayya, Jennifer Green, Sean H. J. Kim, M. Louie-Gao, R. Sawtell, A. Zalutskaya, Byoung Chul Co
{"title":"Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)","authors":"D. Spigel, K. Goto, D. Camidge, Y. Elamin, A. D. de Langen, N. Leighl, A. Minchom, Z. Piotrowska, D. Planchard, K. Reckamp, F. Albayya, Jennifer Green, Sean H. J. Kim, M. Louie-Gao, R. Sawtell, A. Zalutskaya, Byoung Chul Co","doi":"10.1158/1535-7163.targ-21-p230","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"30 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Presentations - Proffered Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1535-7163.targ-21-p230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
